Canaccord raised the firm’s price target on Bioventus to $12 from $8 and keeps a Buy rating on the shares. The firm updated its model to reflect the Q2 results and updated expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS:
- Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference
- Bioventus price target raised to $12 from $9 at Craig-Hallum
- Bioventus sees FY24 EPS 36c-42c, consensus 28c
- Bioventus reports Q2 adjusted EPS 19c, consensus 7c
- Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024